determining the optimal frontline treatment of aml
Published 2 years ago • 65 plays • Length 3:14Download video MP4
Download video MP3
Similar videos
-
5:11
the frontline treatment strategy for newly diagnosed aml
-
3:37
the future of aml treatment
-
1:39
how can mrd guide treatment of aml?
-
5:22
determining the optimal dose of induction therapy for patients with aml
-
5:05
determining the most suitable consolidation therapies for aml by defining patient risk group
-
11:35
optimization of standard aml treatment: apl advances, adverse cytogenetics & post-remission therapy
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
2:09
advances in the management of fit adults with aml
-
19:39
t-cell engagers: targets, challenges and opportunity
-
4:33
maintenance and continuous treatment in acute myeloid leukemia
-
9:45
discussing flt3-mutated aml: top ash data, triplets, and exciting future strategies
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
1:39
optimizing chemotherapy in aml
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:28
assaying flt3 variant allele frequency in aml to determine response to treatment
-
2:45
continuity of care for patients with hematological predispositions to aml
-
1:42
novel treatment combinations in aml: what’s to come?
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
2:08
comparing midostaurin to next-generation flt3 inhibitors in the frontline treatment of flt3-itd aml
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
11:42
aml treatment: what does the data say?